Goldman Sachs analyst Kevin Strang initiates coverage on Erasca Inc (NASDAQ: ERAS) with a Early-Stage Biotech rating.The analyst comments "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage